Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus plus corticosteroids versus mycophenolate mofetil plus corticosteroids for active lupus nephritis
jRCTs031180199Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
01
Overview
Randomised, open-label trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Tacrolimus plus corticosteroids with Mycophenolate mofetil plus corticosteroids (2 arms). Primary endpoint: Maintenance of renal response rate until 96 weeks. Started Apr 2018; status: completed.
02
Drugs
tacrolimusmycophenolate mofetilcorticosteroids
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCTs031180199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180199.